Furthermore, recent studies interestingly demonstrated low relapse rates and more favorable outcomes in older NPM1-mutated and FLT3-ITD negative AML patients consolidated with allogeneic HSCT, challenging the paradigm of a chemotherapy-based consolidation being sufficient in older patient group [56,57]. This evidence concerns the gene FLT3 and acute myeloid leukemia.